Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
This article was originally published in PharmAsia News
Executive Summary
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.